New rheumatoid arthritis drug offers modest benefit with some riskJanuary 21st, 2009 - 1:23 pm ICT by ANI
Washington, Jan 21 (ANI): Anakinra, a new breed of arthritis drugs, has some modest beneficial effect for rheumatoid arthritis patients, but may also have potential risks for serious infections, according to a new study.
The study also warned against its use with other biologic medications.
Rheumatoid arthritis is a chronic inflammatory disease affecting as many as one in 100 people worldwide. It affects the joints, making them stiff and painful.
Belonging to drugs licensed in the past decade called ”biologics”, anakinra is the first to target the immune protein IL-1, thought to be partly responsible for inflammation in arthritis patients. It is given by daily injection.
After conducting a Cochrane Systematic Review of five recent anakinra trials, involving 2,876 patients, the researchers found that the drug reduced pain and stiffness in patients, and helped to improve joint function, when compared to placebo.
While around one-fourth of patients experienced improvement in their symptoms as a result of taking anakinra, it was found that the improvements were notably less than those seen with other biologics.
Besides, there were more injection site reactions with the use of anakinra and also the rate of serious infections with anakinra was touching statistical significance when compared to placebo.
“We would recommend caution with the use of anakinra for rheumatoid arthritis, especially with the only modest beneficial outcomes compared to other biologic medications studied for rheumatoid arthritis,” said lead researcher Dr. Marty Mertens of the University of Minnesota in the US.
One study included in the review investigated the combination of anakinra with another biologic medication, etanercept, and was found to have no benefits in arthritis outcomes.
However, it did show a significant increase in the number of serious adverse events.
“On the basis of these results, we recommend that doctors avoid combining biologic medications with anakinra when treating patients with rheumatoid arthritis,” said Mertens. (ANI)
- Anakinra good for rheumatoid arthritis but also risky, says study - Jan 21, 2009
- New drug limits brain damage in stroke - Jul 27, 2012
- Injectable gel could ease crippling joint pains - Apr 14, 2011
- Aerobic exercise beneficial for rheumatoid arthritis patients - Jun 25, 2010
- New drug restores responsiveness to morphine - Jan 31, 2011
- Anti-depressants ease osteoarthritis pain - Mar 23, 2012
- Celebrex shows potential in preventing some skin cancers - Dec 01, 2010
- Poor response to anti-anemia drug linked to heart disease risk - Dec 29, 2010
- Rheumatoid arthritis medication linked to increased risk for shingles - Feb 18, 2009
- Cuba develops anti-arthritis drug - Feb 17, 2011
- Frequent tipple halves rheumatoid arthritis risk - Jul 11, 2012
- Widely used arthritis pill shows promise against skin cancer - Dec 03, 2010
- Molecule from shark cartilage fights joint pain - Sep 18, 2011
- 'Homeopathy tricks you into feeling better' - Nov 15, 2010
- Obesity epidemic behind rheumatoid arthritis - Apr 26, 2012
Tags: anakinra, arthritis, arthritis drugs, beneficial effect, chronic inflammatory disease, cochrane, etanercept, immune protein, inflammation, jan 21, joints, mertens, new breed, placebo, rheumatoid arthritis, rheumatoid arthritis drug, rheumatoid arthritis patients, serious adverse events, statistical significance, stiffness